Ardelyx

At the Cantor Global Healthcare Conference, Ardelyx confirmed it remains on track to become profitable in 2027, supported by stronger product margins and revenue growth. IBSRELA generated $274 million in revenues in 2024 and is expected to reach $350–370 million in 2025, while XPHOZAH is forecast to remain at $110–120 million for 2025 and paid prescriptions recently rose by 25%. Payers have introduced step-therapy mandates and stricter authorization rules, prompting Ardelyx to increase its reimbursement team and launch digital direct-to-consumer advertising. The company has $282 million in cash, emphasizes patent protection for IBSRELA through 2042, and expects Phase III results for a CIC study in 2026. » Altro su de.investing.com

Ardelyx stock fell 18.4% on Friday to $3.98. Options activity rose to 11,147 contracts, of which 10,676 were puts; 10,004 contracts were for a put expiring October 16, 2026 with a $4 strike. The 3‑month volatility climbed to 74.93% and the 3‑month skew increased markedly, suggesting heightened hedging or speculative short bets. » Altro su de.investing.com

Ardelyx reported record product revenue in Q2 of $118 million (+31% year-on-year), but management lowered the full-year forecast for IBSRELA to $350–370 million and withdrew the previous sales target for XPHOZAH. The company cited tightened payer access restrictions and uncertainty after the end of TDAPA, which is slowing the growth of new patients. The stock fell about 18% in after-hours trading to $3.99 despite improved loss figures and a continued expectation of profitability in 2027. » Altro su de.investing.com

Ardelyx reported Q1 FY2026 total product revenue up 38% year-over-year, driven by a 58% rise in IBSRELA sales and strong XPHOZAH performance. Ladenburg initiated coverage with a Buy and $16 price target, citing expansion of IBSRELA demand, pipeline growth and financial flexibility for further investment. Management aims for at least $1 billion in annual IBSRELA revenue by 2029 while pursuing external opportunities aligned with its capital allocation strategy. » Altro su finance.yahoo.com

At the annual meeting shareholders confirmed three directors (Robert Bazemore, Muna Bhanji, R.Ph, Richard Rodgers) through 2029 and approved the second amendment to the Amended and Restated 2014 Equity Incentive Award Plan. The non-binding say-on-pay vote was approved and the frequency of compensation votes was set to annual. Ernst & Young was ratified as auditor for fiscal 2026. Ardelyx reported a net loss of $37.6 million (‑$0.15 per share) for Q1/2026, missing both EPS and revenue forecasts but cited strong year-over-year growth; the company also presented long-term safety data for XPHOZAH showing no clinically meaningful electrolyte changes. » Altro su de.investing.com